Harrow, Inc.
NASDAQHROW reports today with a short position that has barely budged since yesterday's preview — and the lending market remains tight enough to make a short squeeze a live risk if the print surprises. Short interest is 18.3% of the free float, essentially unchanged from the 18.4% flagged in Monday's preview. What has shifted slightly is borrow availability, which has ticked back up to…
Snapshot as of 16 Aug 2026
HROW reports today with a short position that has barely budged since yesterday's preview — and the lending market remains tight enough to make a short squeeze a live risk if the print surprises. Short interest is…
HROW enters its August 10 print carrying one of the most crowded short positions in the pharmaceutical universe — and the borrow market has tightened sharply in the past week, adding pressure to both sides of the…
Harrow, Inc. enters the second half of 2026 with a sharp internal contradiction — short sellers are rebuilding positions into a stock that just rallied 21% in a month, while options traders are the least bearish…
Harrow, Inc. heads into the back half of 2026 with a striking split in conviction — the co-founders bought the stock aggressively after a steep earnings selloff, while short sellers have quietly added to already…
HROW entered its Q1 print as one of the most shorted small-cap pharma names on Nasdaq. The stock's 24% collapse confirms that heavy positioning wasn't misplaced. Harrow reported Q1 results after the close on May 11.…
Harrow, Inc. heads into its Q1 2026 earnings today with a short book that remains stubbornly elevated — and a stock that has pulled back sharply from this year's highs. Short sellers are not backing down. At 17% of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HROW — free to start on ORTEX.
Sign up for free →Open HROW on ORTEX